[ad_1]
The European Commission accelerates vaccine anti-COVID-19, with the first availability for member countries scheduled for November, and on universal access to drugs. According to Commission officials Ansa, the first availability of the vaccine known as Oxford, on which the Commission has signed a contract that allows member countries to buy 300 million doses with an option for another 100.
Covid, Sanofi and GSK Vaccine: “Trial on 400 People, Promising Results”. 1 billion doses in 2021
Covid, Gemelli Cauda’s infectious diseases specialist: “At Christmas we will deal with the virus, the vaccine will not be there”
Vaccine, Chrysants: “Shortcuts are dangerous”
In addition, after the guarantee of 400 million euros in support of research for the Covax association, next week the EU Executive and the WHO should launch a new mobilization of resources in favor of the WHO Accelerating Law, created to equal access to the vaccine. Meanwhile, negotiations with pharmaceutical companies continue, with the Pfizer-BioNtech vaccine talks well advanced and in the final stages.
An agreement with the American multinational and German biotechnology would establish a diversified group of six candidate vaccines from the companies that are later in the vaccine trial (AstraZeneca, Johnson & Johnson, Sanofi, CureVac, Moderna and Pfizer) for purchase by EU member countries, but also for donation to lower middle income countries or redirection to other European countries.
Last updated: 15:59
© REPRODUCTION RESERVED
[ad_2]
